Evidence map›Paper›PMID 10070840›Full record

ArticleJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology

Radiolabeled MDA2, an oxidation-specific, monoclonal antibody, identifies native atherosclerotic lesions in vivo.

S Tsimikas, W Palinski, S E Halpern, D W Yeung, L K Curtiss, J L Witztum

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 131 citations in OpenAlex.

  1. Review
  2. Molecular Imaging in Drug Discovery and Development.Circulation. Cardiovascular imaging · 2018
    Review
  3. Article
  4. Atheroma and the inflammasome.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2015
    Article
  5. Article
  6. Review
  7. Review
  8. Molecular imaging in cardiovascular disease: Which methods, which diseases?Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2013
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Molecular imaging in atherosclerosis.European journal of nuclear medicine and molecular imaging · 2010
    Review
  17. Review
  18. Article
  19. Molecular imaging in atherosclerosis, thrombosis, and vascular inflammation.Arteriosclerosis, thrombosis, and vascular biology · 2009
    Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

S TsimikasDepartment of Medicine, University of California, San Diego, La Jolla 92093-0682, USA. stsimikas@ucsd.edu
W Palinski
S E Halpern
D W Yeung
L K Curtiss
J L Witztum
University of California, San Diego · USScripps Research Institute · USUniversity of California San Diego Medical Center · US

Funding

Training In Cardiovascular Physiology & PharmacologyT32HL007444 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Ju Chen, Robert Scott Ross · 1985 to 2026
$11.1M
TRANSCRIPTIONAL CONTROL OF GENES INVOLVED IN LDL MODIFICATION AND CATABOLISMP50HL014197 · NHLBI · UNIVERSITY OF CALIFORNIA SAN DIEGO · PI WITZTUM, JOSEPH L · 1985 to 1997
–
NHLBI NIH HHS HL03793NHLBI NIH HHS HL07444NHLBI NIH HHS HL14197
6 · The paper itself

Abstract

backgroundOxidatively modified low-density lipoprotein (LDL) is present in atherosclerotic but not normal arteries and plays a crucial role in the pathogenesis and adverse consequences of atherosclerotic lesions. We previously generated a series of monoclonal antibodies (MoAb) against oxidation-specific neo-epitopes formed during the oxidative modification of LDL. MDA2, a prototype MoAb, recognizes malondialdehyde-lysine epitopes (eg, in malondi-aldehyde-modified LDL) within atherosclerotic lesions. We describe the in vivo characteristics of MDA2 and initial noninvasive imaging studies of atherosclerosis in rabbits.

methodsTo assess the in vivo specificity of MDA2 for atherosclerotic lesions, iodine 125-MDA2 was intravenously injected into 7 LDL-receptor deficient Watanabe heritable hyperlipidemic (WHHL) and 2 normal New Zealand white (NZW) rabbits, and the aortic plaque uptake was evaluated 24 hours later. 125I-Halb, an isotype-matched irrelevant MoAb that binds to human albumin, was injected into 5 WHHL and 2 NZW rabbits as a control. Aortic autoradiography was performed, and the mean uptake of MoAbs was measured as the percent injected dose per gram aortic tissue. Gamma camera imaging was then carried out in 7 WHHL rabbits and 2 NZW rabbits with 99mTc-MDA2. Imaging was carried out at 10 minutes and at 12 or 24 hours. Malondialdehyde-LDL was then injected to clear the blood pool signal, and final images were obtained 2 hours later.

resultsMean uptake of 125I-MDA2 in the entire aorta was 17.4-fold higher in WHHL than in NZW aortas (P < .001), and 2.8-fold higher than 125I-Halb in WHHL aortas. 125I-MDA2 also had higher specificity for lesioned areas than 125I-Halb (plaque/normal ratio 6.3 vs 2.9, P < .001). Autoradiograph of aortas of 125I-MDA2-injected WHHL rabbits revealed uptake in lipid-stained lesions with absence of signal in adjacent normal arterial tissue. Immunostaining of WHHL lesions, which accumulated MDA2 as noted on autoradiography, revealed that uptake was highest in areas with abundant foam cells and in lipid-rich necrotic core areas. Autoradiograph of aortas from NZW rabbits injected with 125I-MDA2 did not yield any visible signal. Planar gamma camera in vivo scintigraphy revealed a visible signal in 4/7 WHHL rabbits, which was confirmed by aortic Sudan staining.

conclusionRadiolabeled MDA2 shows excellent in vivo uptake and specificity for atherosclerotic lesions containing abundant oxidation-specific epitopes. The in vivo imaging studies suggest that noninvasive imaging of oxidation-rich atherosclerotic lesions with radiolabeled MDA2 may be feasible in human beings with optimization of the imaging methods.

Indexed as

Antibodies, MonoclonalRadioimmunodetectionAnimalsAntibody SpecificityAortaArteriosclerosisAutoradiographyEpitopesGamma CamerasImmunohistochemistryLipoproteins, LDLMalondialdehydeOxidation-ReductionRabbitsAntibodies, MonoclonalEpitopesLipoproteins, LDLMalondialdehydeoxidized low density lipoprotein

Identifiers

PMID10070840
OpenAlexW2075951998

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.